+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851837
  • Report
  • August 2018
  • Region: Global
  • 173 pages
  • Transparency Market Research
1 of 2

Global Rheumatoid Arthritis Drugs Market: Overview

This report on the rheumatoid arthritis drugs market analyzes the current and future scenario of the global market. Rise in geriatric population, high prevalence of rheumatoid arthritis, and increase in patient preference for biological origin drugs are major drivers of the global rheumatoid arthritis drugs market.

The rheumatoid arthritis drugs market report comprises an executive summary, which includes a market synopsis that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug type, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, in terms of geography, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global rheumatoid arthritis drugs market.

Global Rheumatoid Arthritis Drugs Market: Key Segments

The global rheumatoid arthritis drugs market can be segmented based on rheumatoid arthritis drug type, distribution channel, and geography. Furthermore, in terms of drug type, the market can be divided into disease-modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics). The biologics segment is likely to account for a leading share of the global rheumatoid arthritis market during the forecast period, owing to wide usage of these drugs in moderate to severe disease condition. Based on distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Rheumatoid Arthritis Drugs Market: Regional Outlook

Based on geography, the global rheumatoid arthritis drugs market has been categorized into five major regions, and the key countries in the respective region are: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2018 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global rheumatoid arthritis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global rheumatoid arthritis drugs market include Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Rheumatoid Arthritis Drugs Market: Market Snapshot

4. Market Overview
4.1. Global Rheumatoid Arthritis Drugs Market: Product Overview
4.2. Global Rheumatoid Arthritis Drugs Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rheumatoid Arthritis Drugs Market Revenue Projections, 2016-2026
4.5. Porter’s Five Forces Analysis

5. Market Outlook
5.1. Pipeline analysis
5.2. Brand Analysis
5.3. Key Mergers and Acquisitions

6. Global Rheumatoid Arthritis Drugs Market Analysis, by Drug Type
6.1. Key Findings
6.2. Introduction
6.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
6.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Drug Type
6.4.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
6.4.2. Corticosteroids
6.4.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.4.4. Biologic Response Modifiers (Biologics)
6.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type

7. Global Rheumatoid Arthritis Drugs Market Analysis, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channels
7.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Distribution Channel
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channels

8. Global Rheumatoid Arthritis Drugs Market Analysis, by Region
8.1. Key Findings
8.2. Global Rheumatoid Arthritis Drugs Market Scenario, by Country
8.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region
8.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Region
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East & Africa
8.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region

9. North America Rheumatoid Arthritis Drugs Market Analysis
9.1. Key Findings
9.2. North America Rheumatoid Arthritis Drugs Market Overview
9.3. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
9.4. North America Rheumatoid Arthritis Drugs Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
9.6. North America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
9.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
9.6.2. Corticosteroids
9.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
9.6.4. Biologic Response Modifiers (Biologics)
9.7. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
9.8. North America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
9.8.1. Hospital Pharmacy
9.8.2. Retail Pharmacy
9.8.3. Online Pharmacy
9.9. North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis

10. Europe Rheumatoid Arthritis Drugs Market Analysis
10.1. Key Findings
10.2. Europe Rheumatoid Arthritis Drugs Market Overview
10.3. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
10.4. Europe Rheumatoid Arthritis Drugs Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
10.6. Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
10.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
10.6.2. Corticosteroids
10.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
10.6.4. Biologic Response Modifiers (Biologics)
10.7. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
10.8. Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
10.8.1. Hospital Pharmacy
10.8.2. Retail Pharmacy
10.8.3. Online Pharmacy
10.9. Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis

11. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis
11.1. Key Findings
11.2. Asia Pacific Rheumatoid Arthritis Drugs Market Overview
11.3. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
11.4. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Country
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
11.6. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
11.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
11.6.2. Corticosteroids
11.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.6.4. Biologic Response Modifiers (Biologics)
11.7. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
11.8. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Pharmacy
11.9. Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis

12. Latin America Rheumatoid Arthritis Drugs Market Analysis
12.1. Key Findings
12.2. Latin America Rheumatoid Arthritis Drugs Market Overview
12.3. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
12.4. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
12.6. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
12.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
12.6.2. Corticosteroids
12.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.6.4. Biologic Response Modifiers (Biologics)
12.6.5. Enteral needles
12.7. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
12.7.1. Hospital Pharmacy
12.7.2. Retail Pharmacy
12.7.3. Online Pharmacy
12.8. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
12.9. Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis

13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Rheumatoid Arthritis Drugs Market Overview
13.3. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
13.4. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Country
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East and Africa
13.5. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
13.6. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
13.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
13.6.2. Corticosteroids
13.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.6.4. Biologic Response Modifiers (Biologics)
13.7. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
13.8. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Pharmacy
13.9. Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis

14. Competitive Landscape
14.1. Company Profiles
14.1.1. AbbVie, Inc.
14.1.1.1. Company Details
14.1.1.2. Business Overview
14.1.1.3. Financial Overview
14.1.1.4. Strategic Overview
14.1.1.5. SWOT Analysis
14.1.2. Janssen Biotech, Inc.
14.1.2.1. Company Details
14.1.2.2. Business Overview
14.1.2.3. Financial Overview
14.1.2.4. Strategic Overview
14.1.2.5. SWOT Analysis
14.1.3. Amgen, Inc.
14.1.3.1. Company Details
14.1.3.2. Business Overview
14.1.3.3. Financial Overview
14.1.3.4. Strategic Overview
14.1.3.5. SWOT Analysis
14.1.4. Pfizer, Inc.
14.1.4.1. Company Details
14.1.4.2. Business Overview
14.1.4.3. Financial Overview
14.1.4.4. Strategic Overview
14.1.4.5. SWOT Analysis
14.1.5. Novartis AG
14.1.5.1. Company Details
14.1.5.2. Business Overview
14.1.5.3. Financial Overview
14.1.5.4. Strategic Overview
14.1.5.5. SWOT Analysis
14.1.6. Sanofi S.A.
14.1.6.1. Company Details
14.1.6.2. Business Overview
14.1.6.3. Financial Overview
14.1.6.4. Strategic Overview
14.1.6.5. SWOT Analysis
14.1.7. F. Hoffmann-La Roche Ltd.
14.1.7.1. Company Details
14.1.7.2. Business Overview
14.1.7.3. Financial Overview
14.1.7.4. Strategic Overview
14.1.7.5. SWOT Analysis
14.1.8. Merck & Co.
14.1.8.1. Company Details
14.1.8.2. Business Overview
14.1.8.3. Financial Overview
14.1.8.4. Strategic Overview
14.1.8.5. SWOT Analysis
14.1.9. Bristol-Myers Squibb Company
14.1.9.1. Company Details
14.1.9.2. Business Overview
14.1.9.3. Financial Overview
14.1.9.4. Strategic Overview
14.1.9.5. SWOT Analysis
14.1.10. Eli Lilly and Company
14.1.10.1. Company Details
14.1.10.2. Business Overview
14.1.10.3. Financial Overview
14.1.10.4. Strategic Overview
14.1.10.5. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll